Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-08 in Multiple Myeloma
NCT03448978Phase 1Terminated
- Sponsor
- Cartesian Therapeutics
- Start
- Mar 2018
- Primary completion
- Apr 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Descartes-08 in multiple myeloma (MM), sponsored by Cartesian Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 weeks. Started Mar 2018; status: terminated.
02
Drugs
Descartes-08
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03448978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448978.